Nombre del producto:1-(1H-imidazole-1-carbonyl)-1H-imidazole

IUPAC Name:1-(1H-imidazole-1-carbonyl)-1H-imidazole

CAS:530-62-1
Fórmula molecular:C7H6N4O
Pureza:98%
Número de catálogo:CM104362
Peso molecular:162.15

Unidad de embalaje Stock disponible Precio($) Cantidad
CM104362-1000g in stock ʼnǵź

Sólo para uso en I+D..

Formulario de consulta

   refresh    

Detalles del producto

Núm. De CAS :530-62-1
Fórmula molecular:C7H6N4O
Punto de fusión:-
Código de sonrisas:O=C(N1C=CN=C1)N1C=CN=C1
Densidad:
Número de catálogo:CM104362
Peso molecular:162.15
Punto de ebullición:394.6°C at 760 mmHg
Nº Mdl:MFCD00005286
Almacenamiento:Protect from the light and Store in a dry place

Category Infos

Imidazoles
Imidazole is an important five-membered nitrogen-containing heterocyclic compound. Among the numerous heterocyclic compounds, imidazole and its derivatives are regarded as a unique and multifaceted scaffold material due to their diverse applications in industrial, organic and pharmaceutical chemistry. Imidazoles interact in different ways with many therapeutic targets, enzymes and receptors in biological systems and thus exhibit a wide range of biological activities. In particular, several imidazoles can be used as clinical drugs to treat various types of cancer with high therapeutic efficacy. Furthermore, imidazoles are one of the most critical segments in the field of anti-covid-19 virus drug discovery due to their ability to interact with active targets in living systems.
Imidazole Manufacturer
As a professional imidazole manufacturer, we can guarantee product quality and delivery time.our company has been committed to supply personalized product solutions to customers,pls consult us.

Column Infos

Cadisegliatin
vTv Therapeutics announces FDA submission for first phase 3 study of Cadisegliatin in patients with type 1 diabetes. Cadisegliatin (TTP399) is developed as an adjunctive therapy to insulin for the treatment of type 1 diabetes, and the phase 3 trial evaluates its safety and efficacy.
Glucokinase (GK) is mainly concentrated in liver cells, and involved in the regulation of glucose metabolism. Cadisegliatin (TTP399) is a liver-selective glucosekinase activator with a mechanism of action different from that of antidiabetic drugs. It binds to the allosteric site of GK and restores innate glucose-regulating capacity of the liver, not disrupting the interaction between GK and GKRP. Cadisegliatin previously received a Breakthrough Therapy designation from the U.S. FDA.